LORFAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LORFAN is an injectable small-molecule NDA approved by Roche in 1956. The specific indication and mechanism of action are not publicly documented in available datasets. This product represents a legacy therapeutic from the mid-20th century pharmaceutical era.
LOE Approaching
LOE-approaching lifecycle suggests a consolidating team focused on legacy product management with limited growth hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LORFAN generates zero linked job postings, indicating minimal active hiring or career movement. Working on this product represents a legacy maintenance role with limited advancement or learning in modern drug development.
Brand Manager (Legacy)Field Sales Representative
Worked on LORFAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.